In a 29-year-old man with ADHD and no known prior medication history, which is more appropriate: Concerta (extended‑release methylphenidate) or Vyvanse (lisdexamfetamine)?

Recommendation for ADHD Treatment in a 29-Year-Old Treatment-Naïve Man

Either Concerta (extended-release methylphenidate) or Vyvanse (lisdexamfetamine) is appropriate as first-line treatment, but the highest-quality evidence from a 2018 network meta-analysis supports amphetamines (including Vyvanse) as the preferred first-choice medication for adults with ADHD based on superior efficacy. 1

Evidence-Based Rationale

Efficacy in Adults

The most comprehensive evidence comes from a 2018 systematic review and network meta-analysis of 133 randomized controlled trials that directly compared medications across age groups 1. In adults specifically:

• Amphetamines (including Vyvanse) demonstrated the strongest efficacy with a standardized mean difference (SMD) of -0.79 compared to placebo
• Methylphenidate (Concerta) showed moderate efficacy with an SMD of -0.49 compared to placebo
• In head-to-head comparisons, amphetamines were superior to methylphenidate in adults (SMD difference of -0.29 to -0.94 favoring amphetamines) 1

This represents high-quality evidence that amphetamines provide greater symptom reduction in adults with ADHD.

Tolerability Considerations

Both medications have similar tolerability concerns in adults 1:

• Vyvanse: Higher dropout rate due to adverse effects (OR 3.26 vs placebo), with common side effects including dry mouth, insomnia, decreased appetite, increased heart rate, and anxiety 2
• Concerta: Also higher dropout rate (OR 2.39 vs placebo) with similar adverse effect profile 3

The tolerability profiles are comparable, so this does not differentiate the two options significantly.

Treatment-Naïve Status Advantage

Your patient's treatment-naïve status is actually favorable for Vyvanse. A 2016 review noted that lisdexamfetamine response was generally similar in treatment-naïve patients and those who had failed previous therapies including methylphenidate 4. This suggests starting with the more efficacious option (Vyvanse) is reasonable rather than following a stepwise approach.

Practical Implementation Algorithm

Start with Vyvanse if:

• No contraindications to amphetamines exist (see screening below)
• Patient prioritizes maximum symptom control
• Patient can tolerate morning dosing

Consider Concerta instead if:

• History of substance use disorder (methylphenidate has lower abuse potential than amphetamines based on pharmacokinetics) 5, 3
• Significant anxiety or cardiovascular concerns (though both require monitoring)
• Patient preference for methylphenidate class
• Insurance or cost considerations favor methylphenidate

Essential Pre-Treatment Screening

Before prescribing either medication, assess for 2, 3:

1. Cardiac contraindications: Known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease
2. Psychiatric risk factors: Screen for bipolar disorder risk, psychosis history, or current severe anxiety
3. Substance use history: Current or past stimulant abuse
4. Blood pressure and heart rate: Establish baseline for monitoring
5. Tics or Tourette's syndrome: Family history and clinical evaluation

Dosing Specifics

Vyvanse (Lisdexamfetamine) 2:

• Start: 30 mg every morning
• Titrate: 20 mg weekly increments
• Target: 50-70 mg/day
• Maximum: 70 mg/day

Concerta (Methylphenidate ER) 3:

• Start: 18-36 mg every morning (adults often start at 18-36 mg)
• Titrate: 18 mg increments weekly
• Target: 54-72 mg/day
• Maximum: 72 mg/day

Common Pitfalls to Avoid

1. Don't underdose: Many patients require doses at the higher end of the therapeutic range for optimal response
2. Monitor cardiovascular parameters: Check blood pressure and pulse at each visit during titration 2
3. Assess for psychiatric emergence: New-onset psychotic or manic symptoms require immediate evaluation and possible discontinuation 2
4. Don't dismiss appetite suppression: Can lead to significant weight loss; monitor weight regularly 2

Guideline Support

Asian practice guidelines consistently recommend methylphenidate as first-line treatment 6, but these guidelines predate the 2018 network meta-analysis showing amphetamine superiority in adults 1. The 2002 practice parameter supports stimulants broadly as first-line 5, but lacks the granular adult-specific data from more recent meta-analyses.

Bottom line: The most rigorous comparative evidence supports starting with Vyvanse in this treatment-naïve adult, unless specific contraindications or patient factors favor Concerta.